Company: ACBM
Filing Date: 2025-07-24
Form Type: 10-K
Source: 0001640334-25-001300
Chunk: 124

Company: ACRO BIOMEDICAL CO., LTD.
Filing Date: 2025-07-24
Form: 10-K
Item: Item 14
Chunk 124
---
792   9,970 Net cash provided by financing activities  36,792   9,970          Net change in cash  100   (5,476)Cash at beginning of period  376   5,852 Cash at end of period $476  $376          SUPPLEMENTAL CASH FLOW INFORMATION:        Cash paid for income taxes $-  $- Cash paid for interest $-  $-          NON CASH INVESTING AND FINANCING ACTIVITIES        Increase in the right-of-use asset and lease liability $-  $52,233 

The accompanying notes are an integral part of these financial statements.

 F-6Table of Contents

ACRO BIOMEDICAL CO., LTD.

Notes to the Financial Statements

NOTE 1 -ORGANIZATION AND DESCRIPTION OF BUSINESS Acro Biomedical Co., Ltd. (the “Company”) is a Nevada corporation incorporated on September 24, 2014 under the name Killer Waves Hawaii, Inc. On January 30, 2017, the Company’s corporate name was changed to Acro Biomedical Co., Ltd. The Company’s business is the sale of cordyceps related products. Cordyceps is a fungus that is used in traditional Chinese medicine. During the second and third quarters of 2021, the Company engaged consultants to take the initial steps to develop and implement a research and development and marketing program. These consultants worked independently and reported to the chief executive officer. The research and development efforts did not generate any product. The contracts with the consultants expired in May 2023 and August 2023. No revenue, new product or new marketing opportunity was generated from these efforts.

NOTE 2 -SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The financial statements have been prepared in accordance with Generally Accepted Accounting Principles (“GAAP”) of the United States. Segment Information Our Chief Executive Officer (“CEO”) is the chief operating decision maker who reviews financial information for purposes of allocating resources and evaluating financial performance. Accordingly, we determined we operate in a single reporting segment. Our CEO assesses performance and decides how to allocate resources primarily based on net income, which is reported on our Statements of Operations. Total assets on the Balance Sheets represent our segment assets. Use of Estimates The preparation of financial statements in conformity with GAAP in the United States